Skip to Content

Join the 'Ferric Citrate' group to help and get support from people like you.

Ferric Citrate News

FDA Approves Auryxia (ferric citrate) Tablets as a Treatment for People with Iron Deficiency Anemia and Chronic Kidney Disease, Not on Dialysis

Posted 13 Nov 2017 by Drugs.com

BOSTON, Nov. 07, 2017 (GLOBE NEWSWIRE) – Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a company focused on bringing innovative medicines to people with kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has approved Auryxia for an additional indication. The approval is for the treatment of iron deficiency anemia in adults with chronic kidney disease (CKD), not on dialysis. Auryxia was originally approved in September 2014 for the control of serum phosphorus levels in people with chronic kidney disease who require dialysis. With the new indication, millions of people living with chronic kidney disease have the potential to benefit from treatment with Auryxia. This medication is available today in pharmacies and covered broadly by Medicare Part D and commercial insurance providers in the United States. “More than half of the approximate 30 million people i ... Read more

Related support groups: Iron Deficiency Anemia, Chronic Kidney Disease, Anemia Associated with Chronic Renal Failure, Auryxia, Ferric Citrate

Keryx Biopharmaceuticals Announces Trade Name Auryxia for Ferric Citrate

Posted 17 Nov 2014 by Drugs.com

NEW YORK, Nov. 17, 2014 (GLOBE NEWSWIRE) – Keryx Biopharmaceuticals, Inc., a biopharmaceutical company focused on bringing innovative therapies to market for patients with renal disease, today announced that the U.S. Food and Drug Administration (FDA) has approved the trade name Auryxia (ferric citrate) for its FDA-approved ferric citrate. Auryxia, an iron-based phosphate binder, was approved by the FDA to control serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis in September 2014. Ron Bentsur, Chief Executive Officer of Keryx, commented, "We are excited to receive FDA approval of the trade name Auryxia. We look forward to launching Auryxia in the U.S. at year end and to providing nephrologists with an effective phosphate binder for dialysis-dependent CKD patients." For more information about Auryxia, please visit www.Auryxia.com. About End Stage ... Read more

Related support groups: Ferric Citrate, Hyperphosphatemia of Renal Failure

Ask a Question

Further Information

Related Condition Support Groups

Hyperphosphatemia of Renal Failure, Iron Deficiency Anemia

Related Drug Support Groups

Auryxia

Ferric Citrate Patient Information at Drugs.com